P/B
7,3
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
$133.2M
Market Cap • 9/28/2026
1995
(31 years)
Founded
2024
(2 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,4
EPS
—
Market Cap
Market Cap
133,2M
EV
136M
EV/Revenue
0
EV/EBITDA
-4,4
EV/EBIT
-4,4
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-15,2%
Total Yield
-15,2%
Payout
0%
Retained Earnings
-157,9M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
223,9%
Capex/OCF
-0,7%
SBC/OCF
—
% PPE
2,3%
% Goodwill
33,8%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
14,2%
CAGR Net Income 5Y
-4,4%
CAGR EPS 5Y
-80,6%
CAGR OCF 5Y
9,5%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
0,2
Quick Ratio
0,1
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!